Source: Nutrition Journal. Unidade: FFCLRP
Subjects: HELICOBACTER PYLORI, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, PLACEBOS, LACTOBACILLUS
ABNT
ZHAO, Yuyang et al. Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial. Nutrition Journal, v. 24, p. 1-12, 2025Tradução . . Disponível em: https://doi.org/10.1186/s12937-025-01124-6. Acesso em: 19 abr. 2026.APA
Zhao, Y., Niu, X., Zhang, Y., Zhao, L., Zhang, L., He, J., et al. (2025). Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial. Nutrition Journal, 24, 1-12. doi:10.1186/s12937-025-01124-6NLM
Zhao Y, Niu X, Zhang Y, Zhao L, Zhang L, He J, Zhang Q, Mao Y, Wang F, Zhao X, Wang R. Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial [Internet]. Nutrition Journal. 2025 ; 24 1-12.[citado 2026 abr. 19 ] Available from: https://doi.org/10.1186/s12937-025-01124-6Vancouver
Zhao Y, Niu X, Zhang Y, Zhao L, Zhang L, He J, Zhang Q, Mao Y, Wang F, Zhao X, Wang R. Impact of supplementing Limosilactobacillus fermentum MN–LF23 on the eradication of Helicobacter pylori with 14–day standard quadruple therapy: a randomized, double–blind, placebo–controlled trial [Internet]. Nutrition Journal. 2025 ; 24 1-12.[citado 2026 abr. 19 ] Available from: https://doi.org/10.1186/s12937-025-01124-6
